002603 以岭药业
已收盘 07-06 15:00:00
资讯
新帖
简况
以岭药业最新公告:全资孙公司获厄贝沙坦原料药上市批准
证券之星 · 07-06 17:32
以岭药业最新公告:全资孙公司获厄贝沙坦原料药上市批准
以岭药业:联动传统媒体、新媒体、户外媒体如各大高铁站大屏等多形式、多场景、多频次内容投放
证券之星 · 07-03
以岭药业:联动传统媒体、新媒体、户外媒体如各大高铁站大屏等多形式、多场景、多频次内容投放
以岭药业:现金分红是公司回报股东的重要方式之一
证券之星 · 07-03
以岭药业:现金分红是公司回报股东的重要方式之一
以岭药业:小儿连花情感颗粒新药注册上市申请已获正式受理
证券之星 · 07-03
以岭药业:小儿连花情感颗粒新药注册上市申请已获正式受理
以岭药业:已有连翘、金银花、酸枣等多个种植基地通过了GAP延伸检查
证券之星 · 07-03
以岭药业:已有连翘、金银花、酸枣等多个种植基地通过了GAP延伸检查
以岭药业:八子补肾胶囊是公司应用气络学说精气神理论指导研发的OTC甲类药品
证券之星 · 07-03
以岭药业:八子补肾胶囊是公司应用气络学说精气神理论指导研发的OTC甲类药品
6月29日以岭药业涨6.00%,长信金利趋势混合A基金重仓该股
证券之星 · 06-29
6月29日以岭药业涨6.00%,长信金利趋势混合A基金重仓该股
以岭药业连续4年参评,2025报告获评“四星半级”|评级档案(编号1927)
证券之星 · 05-25
以岭药业连续4年参评,2025报告获评“四星半级”|评级档案(编号1927)
以岭药业最新公告:全资孙公司磷酸奥司他韦原料药上市申请获批
证券之星 · 05-14
以岭药业最新公告:全资孙公司磷酸奥司他韦原料药上市申请获批
以岭药业:构建专利中药、化生药、健康产业协同发展格局
证券之星 · 05-14
以岭药业:构建专利中药、化生药、健康产业协同发展格局
每周股票复盘:以岭药业(002603)股东户数较前期减少1.8%
证券之星 · 05-03
每周股票复盘:以岭药业(002603)股东户数较前期减少1.8%
以岭药业入选《新财富》杂志“最具国潮品牌力公司”榜单
证券之星 · 04-30
以岭药业入选《新财富》杂志“最具国潮品牌力公司”榜单
以岭药业(002603)3月31日股东户数14.8万户,较上期减少1.8%
证券之星 · 04-28
以岭药业(002603)3月31日股东户数14.8万户,较上期减少1.8%
以岭药业2025年归母净利润12.86亿元同比增277.56%,心脑血管与呼吸类产品营收占比升至76.28%
蓝鲸财经 · 04-28
以岭药业2025年归母净利润12.86亿元同比增277.56%,心脑血管与呼吸类产品营收占比升至76.28%
以岭药业入选“2026中国企业AI+场景创新典范案例”
证券之星 · 04-23
以岭药业入选“2026中国企业AI+场景创新典范案例”
从源头提升中药质量,以岭药业泽泻种植基地通过GAP延伸检查
证券之星 · 04-22
从源头提升中药质量,以岭药业泽泻种植基地通过GAP延伸检查
以岭药业(002603)披露中药新药芪龙定喘片获临床试验批准,3月26日股价下跌0.75%
证券之星 · 03-26
以岭药业(002603)披露中药新药芪龙定喘片获临床试验批准,3月26日股价下跌0.75%
以岭药业(002603.SZ):“非奈利酮”化学原料药上市申请获批
智通财经 · 03-18
以岭药业(002603.SZ):“非奈利酮”化学原料药上市申请获批
以岭药业(002603.SZ):泊马度胺化学原料药上市申请获批准
智通财经 · 03-03
以岭药业(002603.SZ):泊马度胺化学原料药上市申请获批准
以岭药业:公司子公司有部分健康绿农产品
证券之星 · 03-03
以岭药业:公司子公司有部分健康绿农产品
公司概况
公司名称:
石家庄以岭药业股份有限公司
所属行业:
医药制造业
上市日期:
2011-07-28
主营业务:
石家庄以岭药业股份有限公司的主营业务是专利创新中药的研发、生产和销售。公司的主要产品是通心络胶囊、参松养心胶囊、芪苈强心胶囊、连花清瘟胶囊/颗粒、连花清咳片、芪防鼻通片、津力达颗粒、通络明目胶囊、益肾养心安神片、解郁除烦胶囊、枣椹安神口服液、养正消积胶囊、参灵蓝胶囊、八子补肾胶囊、夏荔芪胶囊、乳结泰胶囊、妇血安片。公司荣获国家科技进步一等奖1项、国家科技进步二等奖4项、国家技术发明二等奖1项及省部级科技奖励20余项。
发行价格:
34.56
{"stockData":{"symbol":"002603","market":"SZ","secType":"STK","nameCN":"以岭药业","latestPrice":15.8,"timestamp":1783321416000,"preClose":15.62,"halted":0,"volume":19525273,"delay":0,"changeRate":0.0115,"floatShares":1377000000,"shares":1671000000,"eps":0.8197,"marketStatus":"已收盘","change":0.18,"latestTime":"07-06 15:00:00","open":15.61,"high":16.03,"low":15.43,"amount":309000000,"amplitude":0.0384,"askPrice":15.81,"askSize":210,"bidPrice":15.8,"bidSize":421,"shortable":0,"etf":0,"ttmEps":0.8197,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1783387800000},"marketStatusCode":5,"adr":0,"adjPreClose":15.62,"symbolType":"stock","openAndCloseTimeList":[[1783301400000,1783308600000],[1783314000000,1783321200000]],"highLimit":17.18,"lowLimit":14.06,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1670705376,"isCdr":false,"pbRate":2.29,"roa":"--","peRate":19.275345,"roe":"3.65%","epsLYR":0.77,"committee":0.289406,"marketValue":26397000000,"turnoverRate":0.0142,"status":0,"floatMarketCap":21749000000},"requestUrl":"/m/hq/s/002603/wiki","defaultTab":"wiki","newsList":[{"id":"2649640960","title":"以岭药业最新公告:全资孙公司获厄贝沙坦原料药上市批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2649640960","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649640960?lang=zh_cn&edition=full","pubTime":"2026-07-06 17:32","pubTimestamp":1783330334,"startTime":"0","endTime":"0","summary":"以岭药业(002603.SZ)公告称,公司全资孙公司万洋衡水制药有限公司收到国家药监局下发的《化学原料药上市申请批准通知书》,其提交的“厄贝沙坦”原料药上市申请获批。该药品用于原发性高血压及合并高血压的2型糖尿病肾病治疗,将丰富公司产品线,但短期内不会对当期业绩产生重大影响。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070600024204.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","002603","BK0097","BK0042","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648261634","title":"以岭药业:联动传统媒体、新媒体、户外媒体如各大高铁站大屏等多形式、多场景、多频次内容投放","url":"https://stock-news.laohu8.com/highlight/detail?id=2648261634","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648261634?lang=zh_cn&edition=full","pubTime":"2026-07-03 09:06","pubTimestamp":1783040766,"startTime":"0","endTime":"0","summary":"投资者提问:请问董秘,有看到网络消息,公司在2026年春节期间在高铁站有大量广告推广,是否属实,如果有是在哪些地方有增加广告,我在南京,上海,杭州等地都没有看到以岭药业回复:投资者您好,公司积极加强企业品牌和产品品牌建设,联动传统媒体、新媒体、户外媒体如各大高铁站大屏等多形式、多场景、多频次内容投放,全面提升企业品牌形象与产品知名度,强化用户品牌记忆,从而助力产品终端销售转化。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070300009492.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002603","BK0097","BK0239","BK0188","BK0046","BK0042"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648342606","title":"以岭药业:现金分红是公司回报股东的重要方式之一","url":"https://stock-news.laohu8.com/highlight/detail?id=2648342606","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648342606?lang=zh_cn&edition=full","pubTime":"2026-07-03 09:01","pubTimestamp":1783040469,"startTime":"0","endTime":"0","summary":"证券之星消息,以岭药业07月02日在投资者关系平台上答复投资者关心的问题。现金分红是公司回报股东的重要方式之一,通常情况下,持续稳定的分红也是企业稳健经营的标志之一。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070300009298.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0188","BK0097","BK0239","002603","BK0042"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648341746","title":"以岭药业:小儿连花情感颗粒新药注册上市申请已获正式受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2648341746","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648341746?lang=zh_cn&edition=full","pubTime":"2026-07-03 08:58","pubTimestamp":1783040289,"startTime":"0","endTime":"0","summary":"证券之星消息,以岭药业07月02日在投资者关系平台上答复投资者关心的问题。以岭药业回复:投资者您好,去年8月,公司中药创新药小儿连花情感颗粒新药注册上市申请已获正式受理,后续如有新的进展,公司将及时公告。17个产品中12个纳入国家医保目录,5个进入国家基药目录,在全球50余个国家上市销售,获专利870项,荣获国家科技进步奖等六项国家大奖。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070300009251.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002603","BK0046","BK0239","BK0097","BK0188","BK0042"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648189634","title":"以岭药业:已有连翘、金银花、酸枣等多个种植基地通过了GAP延伸检查","url":"https://stock-news.laohu8.com/highlight/detail?id=2648189634","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648189634?lang=zh_cn&edition=full","pubTime":"2026-07-03 08:54","pubTimestamp":1783040050,"startTime":"0","endTime":"0","summary":"证券之星消息,以岭药业07月02日在投资者关系平台上答复投资者关心的问题。公司现有通过GAP认真基地多少亩?截至目前,以岭药业已有连翘、金银花、酸枣等多个种植基地通过了 GAP 延伸检查。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070300009236.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","BK0046","BK0042","BK0097","002603"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648341856","title":"以岭药业:八子补肾胶囊是公司应用气络学说精气神理论指导研发的OTC甲类药品","url":"https://stock-news.laohu8.com/highlight/detail?id=2648341856","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648341856?lang=zh_cn&edition=full","pubTime":"2026-07-03 08:54","pubTimestamp":1783040049,"startTime":"0","endTime":"0","summary":"八子补肾胶囊是公司应用气络学说精气神理论指导研发的OTC甲类药品,是通过填补肾精、燮理阴阳、温扶元气、充养形神实现抗衰老的代表性品种。研究结果显示,八子补肾胶囊可改善自然衰老小鼠的记忆力和肌肉耐力,逆转自然衰老小鼠增龄性的甲基化变化,显著降低其DNA甲基化年龄并延长其健康寿命。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070300009233.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0097","BK0046","002603","BK0239","BK0042","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647391322","title":"6月29日以岭药业涨6.00%,长信金利趋势混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2647391322","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647391322?lang=zh_cn&edition=full","pubTime":"2026-06-29 16:43","pubTimestamp":1782722586,"startTime":"0","endTime":"0","summary":"证券之星消息,6月29日以岭药业涨6.00%创60日新低,收盘报15.54元,换手率1.98%,成交量27.19万手,成交额4.12亿元。根据2026基金Q1季报公募基金重仓股数据,重仓该股的公募基金共8家,其中持有数量最多的公募基金为长信基金的长信金利趋势混合A。长信金利趋势混合A目前规模为35.61亿元,最新净值0.3943,较上一交易日下跌0.15%,近一年上涨27.87%。长信金利趋势混合A的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062900024575.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0046","002603","BK0042","BK0239","BK0097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638945581","title":"以岭药业连续4年参评,2025报告获评“四星半级”|评级档案(编号1927)","url":"https://stock-news.laohu8.com/highlight/detail?id=2638945581","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638945581?lang=zh_cn&edition=full","pubTime":"2026-05-25 10:27","pubTimestamp":1779676078,"startTime":"0","endTime":"0","summary":"报告评级经“中国企业社会责任报告评级专家委员会”评定,《石家庄以岭药业股份有限公司2025年环境、社会及治理报告》为“四星半级”,是一份领先的企业可持续发展报告。亮点绩效《报告》的实质性、可比性均达到五星级,过程性、平衡性、可读性、创新性达到四星半级,完整性达到四星级。评级勋章以岭药业连续4年参与报告评级,获黄铜级勋章。以岭药业环境、社会及公司治理报告连续4年获评“四星半级”","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2026052500008413.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002603"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635754790","title":"以岭药业最新公告:全资孙公司磷酸奥司他韦原料药上市申请获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2635754790","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635754790?lang=zh_cn&edition=full","pubTime":"2026-05-14 17:33","pubTimestamp":1778751210,"startTime":"0","endTime":"0","summary":"以岭药业(002603.SZ)公告称,公司全资孙公司万洋衡水制药有限公司收到国家药品监督管理局下发的《化学原料药上市申请批准通知书》,其提交的“磷酸奥司他韦”化学原料药上市申请已获批准。该药品用于预防和治疗流行性感冒,2025年奥司他韦制剂销售额为40.72亿元,同比增长15.03%。此次获批将丰富公司产品线,拓展业务领域,但不会对当期经营业绩产生重大影响。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051400030716.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","BK0188","BK0046","002603","BK0239","BK0097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635501767","title":"以岭药业:构建专利中药、化生药、健康产业协同发展格局","url":"https://stock-news.laohu8.com/highlight/detail?id=2635501767","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635501767?lang=zh_cn&edition=full","pubTime":"2026-05-14 08:54","pubTimestamp":1778720052,"startTime":"0","endTime":"0","summary":"石家庄以岭药业股份有限公司创建于1992年,是国内领先的中药创新企业,以络病理论为科学基石,自主研发17个专利中药新药,覆盖心脑血管、呼吸、抗衰老、代谢、神经、肿瘤等多个健康领域。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051400008478.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0097","BK0239","BK0042","BK0188","002603","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632608571","title":"每周股票复盘:以岭药业(002603)股东户数较前期减少1.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2632608571","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632608571?lang=zh_cn&edition=full","pubTime":"2026-05-03 08:12","pubTimestamp":1777767140,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘,以岭药业报收于17.04元,较上周的16.67元上涨2.22%。本周,以岭药业4月28日盘中最高价报17.25元。以岭药业当前最新总市值284.69亿元,在中药板块市值排名8/66,在两市A股市值排名766/5200。本周关注点股本股东变化:股东户数较前期减少1.8%股本股东变化:户均持股市值为19.01万元股本股东变化股东户数变动截至2026年3月31日,公司股东户数为14.8万户,较12月31日减少2712.0户,减幅为1.8%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050300002022.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0046","002603","BK0042","BK0239","BK0097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631450120","title":"以岭药业入选《新财富》杂志“最具国潮品牌力公司”榜单","url":"https://stock-news.laohu8.com/highlight/detail?id=2631450120","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631450120?lang=zh_cn&edition=full","pubTime":"2026-04-30 14:06","pubTimestamp":1777529190,"startTime":"0","endTime":"0","summary":"4月29日,《新财富》杂志揭晓了“2025新财富杂志最佳上市公司”评选结果,以岭药业凭借其在信息披露质量、可持续发展表现、品牌影响力方面的卓越表现,成功入选“最具国潮品牌力公司”榜单。以岭药业此次获评“最具国潮品牌力公司”,源于其深厚的科研底蕴与持续的创新力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2026043000045489.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0046","002603","BK0042","BK0239","BK0097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630723883","title":"以岭药业(002603)3月31日股东户数14.8万户,较上期减少1.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630723883","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630723883?lang=zh_cn&edition=full","pubTime":"2026-04-28 17:53","pubTimestamp":1777369992,"startTime":"0","endTime":"0","summary":"证券之星消息,近日以岭药业披露,截至2026年3月31日公司股东户数为14.8万户,较12月31日减少2712.0户,减幅为1.8%。在中药行业个股中,以岭药业股东户数高于行业平均水平,截至3月31日,中药行业平均股东户数为5.33万户。从股价来看,2025年12月31日至2026年3月31日,以岭药业区间跌幅为1.35%,在此期间股东户数减少2712.0户,减幅为1.8%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042800052856.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","002603","BK0097","BK0239","BK0042","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630934021","title":"以岭药业2025年归母净利润12.86亿元同比增277.56%,心脑血管与呼吸类产品营收占比升至76.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630934021","media":"蓝鲸财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630934021?lang=zh_cn&edition=full","pubTime":"2026-04-28 10:39","pubTimestamp":1777343969,"startTime":"0","endTime":"0","summary":"数据显示,公司2025年实现营业收入78.31亿元,同比增长20.24%;归母净利润12.86亿元,同比增长277.56%;扣非净利润12.22亿元,同比增长254.16%。心脑血管类产品收入达39.56亿元,占总营收比重50.52%;呼吸系统类产品收入20.17亿元,占比25.76%;二者合计贡献76.28%的营业收入,集中度进一步提升。分季度看,2025年第四季度单季实现营业收入19.63亿元,归母净利润2.86亿元,扣非净利润2.55亿元,分别占全年相应指标的25.07%、22.24%和20.90%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1777314940547192712","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["002603"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629881887","title":"以岭药业入选“2026中国企业AI+场景创新典范案例”","url":"https://stock-news.laohu8.com/highlight/detail?id=2629881887","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629881887?lang=zh_cn&edition=full","pubTime":"2026-04-23 17:58","pubTimestamp":1776938301,"startTime":"0","endTime":"0","summary":"4月22日,第五届中国国际软件发展大会企业AI转型创新论坛在京举行。以岭药业凭借“传承与智变——中医药知识智能化重构与全场景创新实践”项目,从全国150余家企业申报的230余个项目中脱颖而出,成功入选“2026中国企业AI+场景创新典范案例”。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2026042300049693.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0042","BK0188","002603","BK0097","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629973900","title":"从源头提升中药质量,以岭药业泽泻种植基地通过GAP延伸检查","url":"https://stock-news.laohu8.com/highlight/detail?id=2629973900","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629973900?lang=zh_cn&edition=full","pubTime":"2026-04-22 14:47","pubTimestamp":1776840472,"startTime":"0","endTime":"0","summary":"4月21日,河北省药品监督管理局发布《中药材GAP延伸检查结果公告》,以岭药业泽泻种植基地通过河北省药监局组织的GAP延伸检查,综合评定符合要求。这是以岭药业继连翘、板蓝根、黄芪、金银花、红花、酸枣仁基地之后,第七个通过GAP延伸检查的种植基地,进一步从源头保证了药品质量。截至目前,以岭药业已在全国20余个省区,通过自建、共建、共享等方式,创建60余个规模化、标准化中药材种养殖基地。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2026042200030019.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0097","BK0188","BK0239","BK0042","002603","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622786965","title":"以岭药业(002603)披露中药新药芪龙定喘片获临床试验批准,3月26日股价下跌0.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622786965","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622786965?lang=zh_cn&edition=full","pubTime":"2026-03-26 22:36","pubTimestamp":1774535776,"startTime":"0","endTime":"0","summary":"截至2026年3月26日收盘,以岭药业报收于15.98元,较前一交易日下跌0.75%,最新总市值为266.98亿元。该股当日开盘16.09元,最高16.31元,最低15.91元,成交额达1.25亿元,换手率为0.56%。近日,石家庄以岭药业股份有限公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》,其申报的中药新药芪龙定喘片获准开展用于慢性阻塞性肺疾病稳定期心肺气虚、痰瘀阻滞证的临床试验。公司后续将按要求开展临床试验,相关研发进展存在不确定性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032600044715.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","BK0239","BK0188","BK0097","002603","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620236249","title":"以岭药业(002603.SZ):“非奈利酮”化学原料药上市申请获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2620236249","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620236249?lang=zh_cn&edition=full","pubTime":"2026-03-18 17:08","pubTimestamp":1773824886,"startTime":"0","endTime":"0","summary":"智通财经APP讯,以岭药业(002603.SZ)发布公告,近日,公司全资孙公司万洋衡水制药有限公司(以下简称“衡水万洋”)收到国家药品监督管理局下发的《化学原料药上市申请批准通知书》,由衡水万洋提交的“非奈利酮”化学原料药上市申请已获批准。本次衡水万洋获得非奈利酮《化学原料药上市申请批准通知书》,表明该原料药符合国家药品注册的有关规定要求,可销售至国内市场,丰富了公司产品线,拓展公司业务领域,目前不会对公司当期经营业绩产生重大影响。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1415437.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"以岭药业(002603.SZ):“非奈利酮”化学原料药上市申请获批","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0097","BK0046","BK0188","BK0042","002603","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616687317","title":"以岭药业(002603.SZ):泊马度胺化学原料药上市申请获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2616687317","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616687317?lang=zh_cn&edition=full","pubTime":"2026-03-03 16:41","pubTimestamp":1772527260,"startTime":"0","endTime":"0","summary":"智通财经APP讯,以岭药业(002603.SZ)公告,公司全资孙公司万洋衡水制药有限公司(简称“衡水万洋”)收到国家药品监督管理局下发的《化学原料药上市申请批准通知书》,由衡水万洋提交的“泊马度胺”化学原料药上市申请已获批准。据公告信息,泊马度胺是第3代免疫调节剂,具有免疫调节、抗血管生成和抗肿瘤作用,对多种恶性血液疾病有效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1409450.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"以岭药业(002603.SZ):泊马度胺化学原料药上市申请获批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002603","BK0046","BK0097","BK0188","BK0042","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616395564","title":"以岭药业:公司子公司有部分健康绿农产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2616395564","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616395564?lang=zh_cn&edition=full","pubTime":"2026-03-03 09:16","pubTimestamp":1772500579,"startTime":"0","endTime":"0","summary":"证券之星消息,以岭药业(002603)03月02日在投资者关系平台上答复投资者关心的问题。投资者提问:观察公司很久了,觉得我们公司很适合制造织布机或者发展绿色环保食品,公司管理层有无以上计划?以岭药业回复:投资者您好,公司子公司故城县茂丰农业科技开发有限公司有部分健康绿农产品。公司目前暂无您提及的相关机器制造业务计划,感谢您的关注!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030300007672.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000061","BK0188","BK0016","BK0046","BK0027","BK0210","BK0097","BK0028","BK0042","002603","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1783374977184,"stockEarnings":[{"period":"1week","weight":0.0167},{"period":"1month","weight":0.0592},{"period":"3month","weight":-0.0273},{"period":"6month","weight":-0.0789},{"period":"1year","weight":0.1065},{"period":"ytd","weight":-0.0444}],"compareEarnings":[{"period":"1week","weight":-0.008},{"period":"1month","weight":0.0034},{"period":"3month","weight":0.0388},{"period":"6month","weight":-0.0109},{"period":"1year","weight":0.1638},{"period":"ytd","weight":0.0182}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"石家庄以岭药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"148000人(较上一季度减少1.80%)","perCapita":"9300股","listingDate":"2011-07-28","address":"河北省石家庄市裕华区高新技术产业开发区天山大街238号","registeredCapital":"167070万元","survey":" 石家庄以岭药业股份有限公司的主营业务是专利创新中药的研发、生产和销售。公司的主要产品是通心络胶囊、参松养心胶囊、芪苈强心胶囊、连花清瘟胶囊/颗粒、连花清咳片、芪防鼻通片、津力达颗粒、通络明目胶囊、益肾养心安神片、解郁除烦胶囊、枣椹安神口服液、养正消积胶囊、参灵蓝胶囊、八子补肾胶囊、夏荔芪胶囊、乳结泰胶囊、妇血安片。公司荣获国家科技进步一等奖1项、国家科技进步二等奖4项、国家技术发明二等奖1项及省部级科技奖励20余项。","listedPrice":34.56},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"以岭药业(002603)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供以岭药业(002603)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"以岭药业,002603,以岭药业股票,以岭药业股票老虎,以岭药业股票老虎国际,以岭药业行情,以岭药业股票行情,以岭药业股价,以岭药业股市,以岭药业股票价格,以岭药业股票交易,以岭药业股票购买,以岭药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"以岭药业(002603)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供以岭药业(002603)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}